Comparison of efficacy of sitagliptin dose-up and that of glimepiride dose-up in Japanese subjects with type 2 diabetes inadequately controlled on combination therapy with sitagliptin and glimepiride

Comparison of efficacy of sitagliptin dose-up and that of glimepiride dose-up in Japanese subjects with type 2 diabetes inadequately controlled on combination therapy with sitagliptin and glimepiride - sitagliptin and glimepiride randomized study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009544

Enrollment

Registered

2013-03-31

Start date

2012-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

+50 mg/day sitagliptin dose-up +0.5 mg/day glimepiride dose-up

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes treated with sitagliptin (50 mg/day) in addition to glimepiride (<2.0 mg/day) with or without metformin at a stable dosage for at least 16 weeks, aged >20 years, HbA1c level >6.9%, and no improvement in HbA1c within 12 weeks

Exclusion criteria

Exclusion criteria: Subjects with type 1 diabetes, secondary diabetes, severe renal disease, severe hepatic disease, alcoholism, severe depression or severe psychological condition, malignancy or abnormal hemoglobinemia were excluded.

Design outcomes

Primary

Measure	Time frame
% change in HbA1c	—

Secondary

Measure	Time frame
% change in BMI, FPB and urinary 8-OHdG	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026